Jade Biosciences (JBIO) Other Operating Expenses (2025)
Jade Biosciences' (JBIO) quarterly Other Operating Expenses came in at $27.0 million in Q4 2025, up 15122.78% on a QoQ basis from -$180000.0 in Q2 2025.
Powered by 
Analysis
Jade Biosciences (JBIO) Other Operating Expenses (2025) Analysis & Trends
Jade Biosciences (JBIO) has 2 years of Other Operating Expenses data on file, last reported at $27.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Jade Biosciences | 1.22 Bn | 1.22 Bn | - |